目的：探讨T细胞非霍奇金淋巴瘤（T-cell non-Hodgkin’s lymphoma，T-NHL）的不良预后因素，研究CHOPE方案结合左旋门冬酰胺酶（L-asparaginase，L-ASP）治疗T-NHL的疗效及不良反应。方法：收集2007年7月至2013年8月收治的61例T-NHL患者，随机分为两组CHOPE和CHOPE+L组(在CHOPE基础上，第1、3、5、7、9、11天加用L-ASP)，并对其预后相关因素进行分析。结果： 61例T-NHL患者，随访时间为3~65个月，中位随访时间22个月，完全缓解率52.50%，部分缓解率 29.51%，总有效率为80.01%。CHOPE+L组完全缓解率57.89%，总有效率84.21%；CHOPE组完全缓解率43.48%，总有效率78.26%，两组间差异无统计学意义（P>0.05）。T-NHL患者的1年、2年及5年生存率分别为91.0%、87.6%、65.7%，两组患者的总体生存时间差异无统计学意义（P>0.05）。43例结外鼻型自然杀伤/T细胞淋巴瘤（extranodal NK/Tcell lymphoma，nasal type，ENKTCL）患者中，34例接受CHOPE+L方案、9例接受CHOPE方案，两组患者的总生存时间差异有统计学意义（P<0.01)。患者的预后不良因素有ENKTCL新模型、结外病变数和化疗能否达到完全缓解。结论：CHOPE+L是治疗ENKTCL的有效方案，可提高患者的生存率，改善预后。CHOPE+L能否作为T-NHL治疗方案，尚需扩大样本进一步研究。

Objective：To investigate prognostic factors of the T-cell non-Hodgkin’s lymphoma (T-NHL), and to study the clinical efficacy of CHOPE plus L-asparaginase(L-ASP) regimen for T-NHL. Methods:  Retrospective analyses were made of 61 T-NHL patients who were treated from July 2007 to August 2013. Randomly divided into two groups CHOPE and CHOPE+L group(Based on CHOPE, added with L-ASP on the 1st, 3rd, 5th, 7th, 9th and 11th day).Results:  Of the 61 patients evaluatd with the median survival was 22 (3-65) months，the complete remission rate was 52.50%, the partial remission rate 29.51%, and the response rate 80.01%. The complete remission rate was 57.89%, and the patial remission rate 84.21% in CHOPE+L and the complete remission rate 43.48%, the response rate 78.26% in CHOPE, respectively (both P>0.05). The 1-, 2-, and 5-year overall survival rates were 91.0%, 87.6% and 65.7% respectively (P>0.05). But the overall survival rate in CHOPE+L was significantly higher than that in CHOPE group in extranodal NK/T-cell lymphoma, nasal type(ENKTCL) (P<0.05). The analysis of the prognostic factors indicated that ENKTCL, the outside junction lesions, and the CR rate were poor factors with statistic significance in T-NHL. Conclusion:  CHOPE+L regimen has better efficacy for ENKTCL, but whether CHOPE+L regimen is used in the treatment of T-NHL, large prospective clinical trials are worth for further investigation.